Neuroendocrine Tumour as a Diagnostic and Prognostic Criterion for Autoimmune Gastritis
https://doi.org/10.22416/1382-4376-2019-29-6-49-59
Abstract
Aim. To describe modern approaches to the diagnosis and treatment of neuroendocrine gastric tumours associated with chronic autoimmune gastritis on the example of a clinical case.
General provisions. Patient H., born in 1948, suffered from a dyspepsia syndrome, the presence of chronic exhelicobacter gastritis and neuroendocrine tumour of unclear histogenesis in the upper third of the stomach body. The patient also suffered from systemic lupus erythematosus with skin lesions (discoid rash, palmar and plantar capillaries) and joint lesions (migrating polyarthritis). A general clinical examination revealed mild chronic iron deficiency anemia and increased neuron-specific enolase (NSE). An EGDS examination using expert-class equipment with the NBI function of close focus identified subepithelial formations of the stomach body. The histological results showed a morphological pattern consistent with a highly differentiated neuroendocrine tumour (G1), type 1, associated with chronic autoimmune gastritis.
Conclusion. The autoimmune genesis of the chronic inflammation of the gastric mucosa may serve as a background for the development of neuroendocrine tumours of the stomach, which determines the management tactics in such conditions.
General provisions. Patient H., born in 1948, suffered from a dyspepsia syndrome, the presence of chronic exhelicobacter gastritis and neuroendocrine tumour of unclear histogenesis in the upper third of the stomach body. The patient also suffered from systemic lupus erythematosus with skin lesions (discoid rash, palmar and plantar capillaries) and joint lesions (migrating polyarthritis). A general clinical examination revealed mild chronic iron deficiency anemia and increased neuron-specific enolase (NSE). An EGDS examination using expert-class equipment with the NBI function of close focus identified subepithelial formations of the stomach body. The histological results showed a morphological pattern consistent with a highly differentiated neuroendocrine tumour (G1), type 1, associated with chronic autoimmune gastritis.
Conclusion. The autoimmune genesis of the chronic inflammation of the gastric mucosa may serve as a background for the development of neuroendocrine tumours of the stomach, which determines the management tactics in such conditions.
About the Authors
S. I. Mozgovoi
Omsk State Medical University
Dr. Sci. (Med.), Prof., Department of Pathological Anatomy
644099, Omsk, Lenina str., 12
M. A. Livzan
Omsk State Medical University
Dr. Sci. (Med.), Prof., Departmental Head, Department of Therapy and Occupational (Professional) Diseases
644099, Omsk, Lenina str., 12
Dr. Sci. (Med.), Prof., Departmental Head, Department of Therapy and Occupational (Professional) Diseases
644099, Omsk, Lenina str., 12
T. S. Krolevets
Omsk State Medical University
Russian Federation
Cand. Sci. (Med.), Assist., Departmental Head, Department of Therapy and Occupational (Professional) Diseases
644099, Omsk, Lenina str., 12
Russian Federation
Cand. Sci. (Med.), Assist., Departmental Head, Department of Therapy and Occupational (Professional) Diseases
644099, Omsk, Lenina str., 12
A. G. Shimanskaya
Omsk State Medical University
Cand. Sci. (Med.), Assoc. prof., Department of Pathological Anatomy
644099, Omsk, Lenina str., 12
Cand. Sci. (Med.), Assoc. prof., Department of Pathological Anatomy
644099, Omsk, Lenina str., 12
References
1. Massironi S., Cavalcoli F., Rossi R.E., et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol2013;168:755-761. doi: 10.1530/EJE-12-1067.
2. Anlauf M., Gerlach P., Schott M., Raffel A., Krausch M., Knoefel W.T., Pavel M., Kloppel G. Pathology of neuroendocrine neoplasms. Chirurg. 2011;82(7):567–573.
3. Amerio P., Tracanna M., De Remigis P., et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3 B+C and 4. ClinExpDermatol 2006;31:746-749. DOI: 10.1111/j.1365-2230.2006.02171.x
4. Caplin M., Yao J.C. An overview of thoracic and gastrointestinal neuroendocrine tumours. In: M. Caplin, J.C. Yao (eds.). Handbook of Gastroenteropancreatic and Thoracic Neuroendocrine Tumours. BioScientifica. 2011. P. 1–9.
5. Livsan M.A., Osipenko M.F., Zayakina Natalya V., Krolevets T.S. THE MANY FACES OF THE PROBLEM OF INTOLERANCE TO GLUTEN. Clinical Medicine. 2018;96(2);123-128. (in Russ.)
6. Gianfranco DelleFave, Dik J. Kwekkeboom, Erik Van Cutsem, Guido Rindi, Beata Kos-Kudla, Ulrich Knigge, Hironobu Sasano, Paola Tomassetti, Ramon Salazar, Philippe Ruszniewski, all other Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012;95:74–87. DOI: 10.1159/000335595
7. Oshima T., Okugawa T., Hori K., Kim Y., Tanaka J., Watari J., Miwa H. Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus. InternMed. 2012;51(10):1211-3. DOI: 10.2169/internalmedicine.51.7077
8. G. DelleFave, A. Sundin, B. Taal, P. Ferolla, J.K. Ramage, D. Ferone, T. Ito, W. Weber, Z. Zheng-Pei, W.W. De Herder, A. Pascher, P. Ruszniewski, all other Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology 2016;103:119–124. DOI: 10.1159/000443168
9. Döcker D., Marx U., Braun B. Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus. AbstractSend to Dtsch Med Wochenschr. 2010 Sep;135(36):1723-6. doi: 10.1055/s-0030-1263306.
10. Livzan M.A., Lyalyukova E.A., Kostenko M.B. Non-steroid anti-inflammatory preparations: risk assessment and ways of the therapy safety enhancement. Lechashhij vrach. 2016;5:78 (In Rus.)
11. Neumann W.L., et al. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529–41. DOI: 10.1038/nrgastro.2013.101
12. Bohjan V.Ju., Bel’cevich D.G., Vashakmadze L.A. et al. Clinical recommendations for the treatment of neuroendocrine tumors. All-Russian Union of Public Associations. Association of Oncologists of Russia. Approved at the Board meeting of the Association of Oncologists of Russia. Moscow; 2014. 28 p. (In Rus.)
13. Cavallaro A., Zanghì A., Cavallaro M. et al: The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. Int J Surg 2014; 12(suppl 1):S225–S231. doi: 10.1016/j.ijsu.2014.05.017.
14. Rugge M., Correa P., Di Mario F. et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40(8):650-8. DOI: 10.1016/j.dld.2008.02.030
15. Alexander H.R., Fraker D.L., Norton J.A., Barlett D.L., Tio L., Benjamin S.B., Doppman J.L., Goebel S.U., Serrano J., Gibril F., Jensen R.T. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg1998;228:228–238. https://www.ncbi.nlm.nih.gov/pubmed/9712569
16. Niederle M.B., Hackl M., Kaserer K. et al: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. EndocrRelatCancer2010;17:909–918. doi: 10.1677/ERC-10-0152.
17. Rindi G., Klimstra D.S., Abedi-Ardekani B., Asa S.L. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y.
18. Rindi G, Luinetti O, Cornaggia M, et al: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994–1006. https://moh-it.pure.elsevier.com/en/publications/three-subtypes-of-gastric-argyrophil-carcinoid-and-the-gastric-ne
19. Lahner E., Norman G.L., Severi C., et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104(8):2071–79. doi: 10.1038/ ajg.2009.231.
20. Coburn N. et al. Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treat. Rev. 2018; 63:104-115. doi: 10.1016/j.ctrv.2017.12.006.
21. Tozzoli R, Kodermaz G., Perosa A.R., et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev. 2010;10(2):80–3. Doi: 10.1016/j.autrev.2010.08.006
22. Vannella L, Sbrozzi-Vanni A, Lahner E, etal: Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment PharmacolTher2011;33:1361–1369. doi: 10.1111/j.1365-2036.2011.04659.x.
23. Tozzoli R. The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases. ClinChem Lab Med. 2008;46(5): 577–87.
24. Borch K, Ahren B, Ahlman H, et al: Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64–73. https://www.ncbi.nlm.nih.gov/pubmed/15973103
25. Weck M.N., Brenner H. Association of Helicobacter pylori infection with chronic atrophic gastritis: Meta-analyses according to type of disease definition. Int. J. Cancer. 2008;123: 874–881. doi: 10.1002/ijc.23539.
26. Vanella Marignani M, Delle Fave G, Mecarocci S, et al: High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia. A prospective screening study. Am J Gastroenterol 1999;94:766–772. https://www.ncbi.nlm.nih.gov/pubmed/10086664
27. Amedei, A., Bergman, M.P., Appelmelk, B., et al. Molecular mimicry between Helicobacter pylori antigens and H+K+-adenotriphosphatase in human gastric autoimmunity. J. Exp. Med. 2003;198:1147–1156. https://www.ncbi.nlm.nih.gov/pubmed/14568977
28. Merola E, Sbrozzi-Vanni A, Panzuto F, et al: Type I gastric carcinoids: a prospective study on endoscopic management and recurrencerate. Neuroendocrinology 2011 (E-pub ahead of print).
29. Niikura R, Hayakawa Y, Hirata Y, Ogura K, Fujishiro M, Yamada A, Ushiku T, Konishi M, Fukayama M, Koike K. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion. Int J MolSci. 2019;20(8). pii: E1913. doi: 10.3390/ijms20081913.
30. F. Gibril, M. Schumann, A. Pace, and R. T. Jensen. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine. 2004;83:43–83. https://www.ncbi.nlm.nih.gov/pubmed/14747767
31. Livzan M.A., Mozgovoj S.I., Kononov A.V. Gastritis after eradication of Helicobacter pylori — simple traces or serious consequences? Lechashchij vrach. 2011;7:7 (In Rus.)
32. Bordi C., Falchetti A., Azzonietal C. Aggressive form sofgastric neuroendocrine tumors in multiple endocrine neoplasia type I. American Journal of Surgical Pathology. 1997;21(9):1075–1082. https://www.pubfacts.com/detail/9298884/Aggressive-forms-of-gastric-neuroendocrine-tumors-in-multiple-endocrine-neoplasia-type-I
33. Livzan M.A., Kononov A.V., Mozgovoj S.I. Post-eradication period of chronic gastritis associated with Helicobacter pylori infection. Consilium Medicum. 2008;10(8):15–20. (In Rus.)
34. J. A. Norton, M. L. Melcher, F. Gibril, and R. T. Jensen. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136(6):1267–1274. https://www.ncbi.nlm.nih.gov/pubmed/15657586
35. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708–16. DOI: https://doi.org/10.1016/j.ejca.2006.01.020.
36. M. M. Hassan, A. Phan, D. Li, C. G. Dagohoy, C. Leary, and J. C. Yao. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. International Journal of Cancer. 2008;123(4):867–873. doi: 10.1002/ijc.23529.
37. Correa P. The biological model of gastric carcinogenesis. IARC SciPubl. 2004;157:301–11.
38. A. Ooi, M. Ota, S. Katsuda, I. Nakanishi, H. Sugawara, and I. Takahashi. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocrine Pathology. 1995;6(3):229–237. https://www.ncbi.nlm.nih.gov/pubmed/12114744
39. Livzan M.A., Kononov A.V., Mozgovoj S.I. The course of chronic gastritis associated with Helicobacter pylori in the post-eradication period. Experimental and clinical gastroenterology. 2007;5:116–123. (In Rus.)
40. C. M. Zhao and D. Chen. The ECL cell: relay station for gastric integrity. Current Medicinal Chemistry. 2012;19(1):98–108. https://www.ncbi.nlm.nih.gov/pubmed/22300082
41. M. F. Fanelli, L. T. Chinen, M. D. Begnami et al. The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012;61(2):153–161. doi: 10.1111/j.1365-2559.2011.04139.x.
42. N. Hodgson, L. G. Koniaris, A. S. Livingstone, and D. Franceschi. Gastric carcinoids: a temporal increase with proton pump introduction. Surgical Endoscopy and other Interventional Techniques. 2005;19(12):1610–1612. https://www.ncbi.nlm.nih.gov/pubmed/16211437
43. M. Germain and R. S. Slack. MCL-1 regulates the balance between autophagy and apoptosis. Autophagy. 2011;7(5):549–551. https://doi.org/10.4161/auto.7.5.15098
44. Massironi S., Cavalcoli F., Rossi R.E. et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol. 2013;168:755-61. doi: 10.1530/EJE-12-1067.
45. Mozgovoy S.I., Kostenko M.B., Krolevets T.S., Livzan M.A. Autoimmune gastritis in the focus of clinician and morphologist. Farmateka. 2019;26(2):121–29. (in Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2019.2.121-129
46. Jakovenko Je.P., Ivanov A.N., Illarionova Ju.V. i dr. Hronicheskij gastrit: diagnostika i lechenie. Farmateka. 2009;8:50–54. (in Russ.)
47. Massironi S., Cavalcoli F., Rossi R.E., et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol2013;168:755-761. doi: 10.1530/EJE-12-1067.
48. Amerio P., Tracanna M., De Remigis P., et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3 B+C and 4. ClinExpDermatol 2006;31:746-749. DOI: 10.1111/j.1365-2230.2006.02171.x
49. Livsan M.A., Osipenko M.F., Zayakina Natalya V., Krolevets T.S. THE MANY FACES OF THE PROBLEM OF INTOLERANCE TO GLUTEN. Clinical Medicine. 2018;96(2);123-128. (in Russ.)
50. Oshima T., Okugawa T., Hori K., Kim Y., Tanaka J., Watari J., Miwa H. Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus. InternMed. 2012;51(10):1211-3. DOI: 10.2169/internalmedicine.51.7077
51. Döcker D., Marx U., Braun B. Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus. AbstractSend to Dtsch Med Wochenschr. 2010 Sep;135(36):1723-6. doi: 10.1055/s-0030-1263306.
52. Neumann W.L., et al. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529–41. DOI: 10.1038/nrgastro.2013.101
53. Cavallaro A., Zanghì A., Cavallaro M. et al: The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. Int J Surg 2014; 12(suppl 1):S225–S231. doi: 10.1016/j.ijsu.2014.05.017.
54. Alexander H.R., Fraker D.L., Norton J.A., Barlett D.L., Tio L., Benjamin S.B., Doppman J.L., Goebel S.U., Serrano J., Gibril F., Jensen R.T. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg1998;228:228–238. https://www.ncbi.nlm.nih.gov/pubmed/9712569
55. Rindi G., Klimstra D.S., Abedi-Ardekani B., Asa S.L. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y.
56. Lahner E., Norman G.L., Severi C., et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104(8):2071–79. doi: 10.1038/ ajg.2009.231.
57. Tozzoli R, Kodermaz G., Perosa A.R., et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev. 2010;10(2):80–3. Doi: 10.1016/j.autrev.2010.08.006
58. Tozzoli R. The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases. ClinChem Lab Med. 2008;46(5): 577–87.
59. Weck M.N., Brenner H. Association of Helicobacter pylori infection with chronic atrophic gastritis: Meta-analyses according to type of disease definition. Int. J. Cancer. 2008;123: 874–881. doi: 10.1002/ijc.23539.
60. Amedei, A., Bergman, M.P., Appelmelk, B., et al. Molecular mimicry between Helicobacter pylori antigens and H+K+-adenotriphosphatase in human gastric autoimmunity. J. Exp. Med. 2003;198:1147–1156. https://www.ncbi.nlm.nih.gov/pubmed/14568977
61. Niikura R, Hayakawa Y, Hirata Y, Ogura K, Fujishiro M, Yamada A, Ushiku T, Konishi M, Fukayama M, Koike K. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion. Int J MolSci. 2019;20(8). pii: E1913. doi: 10.3390/ijms20081913.
62. Livzan M.A., Mozgovoj S.I., Kononov A.V. Gastritis after eradication of Helicobacter pylori — simple traces or serious consequences? Lechashchij vrach. 2011;7:7 (In Rus.)
63. Livzan M.A., Kononov A.V., Mozgovoj S.I. Post-eradication period of chronic gastritis associated with Helicobacter pylori infection. Consilium Medicum. 2008;10(8):15–20. (In Rus.)
64. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708–16. DOI: https://doi.org/10.1016/j.ejca.2006.01.020.
65. Correa P. The biological model of gastric carcinogenesis. IARC SciPubl. 2004;157:301–11.
66. Livzan M.A., Kononov A.V., Mozgovoj S.I. The course of chronic gastritis associated with Helicobacter pylori in the post-eradication period. Experimental and clinical gastroenterology. 2007;5:116–123. (In Rus.)
Review
For citations:
Mozgovoi S.I., Livzan M.A., Krolevets T.S., Shimanskaya A.G. Neuroendocrine Tumour as a Diagnostic and Prognostic Criterion for Autoimmune Gastritis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):49-59. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-6-49-59
Views:
1773
Email this article 
